R: IMPROVED NANOBACTERIA TESTS
- From: "pedrop" <pedrop61@xxxxxxxxx>
- Date: Thu, 17 Nov 2005 08:06:54 GMT
What about nanobacteria and autoimmune deseases such as LES, SS, CREST ?
NanoBiotech Reviews <gmezo@xxxxxxxxxxxxxx> wrote in message
1130343534.445783.203080@xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
> Nanobac Introduces New Improved ELISA Kits for Detection of Calcifying
> Nano-Particles, also known as Nanobacteria
> 10/26/2005 8:00:00 AM EST
> Nanobac Life Sciences, Inc. (OTCBB: NNBP) ("Nanobac" or "the Company")
> announced today the introduction of two new versions of its
> NANOCAPTURE(TM) and NANO-SERO(TM) ELISA test kits for the detection of
> Calcifying Nano-Particles (CNPs), also known as nanobacteria, in serum
> or plasma. The new kits offer improved sensitivity, lower background
> and improved stability over the previous versions. Nanobac has added
> new standards to improve precision at the low end and freeze dried the
> critical components for improved stability.
> "Our demand for CNP diagnostic products is increasing as CNP's or
> nanobacteria are implicated in more and more chronic diseases," stated
> Grant Carlson, Nanobac's President and Chief Operating Officer.
> "Nanobac has worked hard to develop robust, sensitive and reproducible
> ELISA test kits for the CNP/nanobacteria research community. These kits
> are CE marked and ready for immediate shipment throughout the European
> Union. In the United States the kits will be sold For Research Use Only
> (RUO)."
> The NANOCAPTURE ELISA is a two-site immunoenzymatic assay for the
> quantitative measurement of CNP/nanobacterial antigen in serum or
> plasma. The NANO-SERO ELISA is also a two site immunoenzymatic assay
> for the quantitative measurement of anti-CNP antibodies in serum or
> plasma. Nanobac will feature the NANOCAPTURE and NANO-SERO ELISA test
> kits at the world's #1 medical trade show, MEDICA, in Dusseldorf,
> Germany, November 16-19, 2005. Last year the show attracted 136,000
> visitors from around the world. Nanobac intends to meet with potential
> customers and establish its global network of in vitro diagnostic
> distributors.
> About Nanobac Life Sciences
> Nanobac Life Sciences, Inc. is a broad-based life science company that
> discovers, develops, manufactures, and markets a range of products and
> services to improve people's health through the detection and treatment
> of Calcifying Nano-Particles, otherwise known as "nanobacteria". The
> Company's pioneering research is establishing the pathogenic role of
> nanobacteria in soft tissue calcification, particularly in coronary
> artery heart disease, prostatitis and vascular disease.
> Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and
> reagents for the detection of Calcifying Nano-Particles. IVD products
> include the NANOCAPTURE(TM) and NANO-SERO(TM) ELISA assays and the
> Nano-Vision(TM) line of antibodies and reagents. Nanobac's
> BioAnalytical Services works with biopharmaceutical partners to develop
> and apply methods for avoiding, detecting, and inactivating or
> eliminating CNPs from raw materials. Nanobac's Drug Discovery and
> Development efforts are focused on developing new and existing
> compounds that effectively inhibit, destroy or neutralize CNPs. The
> Company also markets Dietary Supplements through its subsidiary,
> Nanobac Sciences, LLC.
> Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For
> more information, please visit our website at: http://www.nanobac.com.
> Investors are cautioned that certain statements contained in this
> document as well as some statements in periodic press releases and some
> oral statements of Nanobac Life Sciences, Inc. officials are
> "Forward-Looking Statements" within the meaning of the Private
> Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking
> statements include statements which are predictive in nature, which
> depend upon or refer to future events or conditions, which include
> words such as "believes," "anticipates," "intends," "plans," "expects,"
> and similar expressions. In addition, any statements concerning future
> financial performance (including future revenues, earnings or growth
> rates), ongoing business strategies or prospects, and possible future
> Nanobac Life Sciences, Inc. actions, which may be provided by
> management, are also forward-looking statements as defined by the Act.
> Forward-Looking statements involve known and unknown risks,
> uncertainties, and other factors which may cause the actual results,
> performance or achievements of the Company to materially differ from
> any future results, performance or achievements expressed or implied by
> such forward-looking statements and to vary significantly from
> reporting period to reporting period. Although management believes that
> the assumptions will, in fact, prove to be correct or that actual
> future results will not be different from the expectations expressed in
> this report. These statements are not guarantees of future performance
> and Nanobac Life Sciences, Inc. has no specific intention to update
> these statements.
> CONTACT:
> Nanobac Life Sciences, Inc. John Stanton, CEO or Grant Carlson,
> President/COO
> Telephone: (813) 264-2241
> Website: www.nanobaclabs.com
>
>
.
- Follow-Ups:
- Re: R: IMPROVED NANOBACTERIA TESTS
- From: NanoBiotech Reviews
- Re: R: IMPROVED NANOBACTERIA TESTS
- Prev by Date: Re: Question about MT joining MLT union
- Next by Date: Technichal question about frozen sections
- Previous by thread: Question about 5 year olds blood test
- Next by thread: Re: R: IMPROVED NANOBACTERIA TESTS
- Index(es):
Relevant Pages
|
